Molecular Hydrogen Therapy in Aneurysmal SAH With RA and Newly-diagnosed SLE, Complicated With Acute Ischemic Infarction: A Case Report of Improved Immune Markers Including Tr1 Cells, Breg Cells and TIM3 Expression on Tc Cells.
Jing-Yuan Chen, Jeng-Wei Lu, Shao-Wei Feng, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Feng-Cheng Liu · In vivo (Athens, Greece) · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells, and the conversion of anti-dsDNA from positive to ne.
What the Researchers Studied
The researchers studied The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells, and the conversion of anti-dsDNA from positive to ne.
What Effects Did Molecular Hydrogen Have?
The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells, and the conversion of anti-dsDNA from positive to negative. This case highlights the potential benefits of molecular hydrogen therapy in managing aneurysmal SAH with underlying autoimmune disease, warranting further research. By reducing oxidative stress and inflammation, hydrogen therapy may foster a more favorable environment for the function of Tr1 and Breg cells, and enhance TIM3 expression, thereby contributing to improved immune tolerance in autoimmune diseases.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells, and the conversion of anti-dsDNA from positive to ne.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.